Cost effectiveness of fecal DNA screening for colorectal cancer: A systematic review and quality appraisal of the literature

Applied Health Economics and Health Policy

Volumn 11, Issue 3, 2013, Pages 181-192

  Skally, Mairead ^a   Hanly, Paul ^a   Sharp, Linda ^a  

^a NATIONAL CANCER REGISTRY IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

CANADA; CANCER SCREENING; CHECKLIST; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DNA SCREENING; FECES ANALYSIS; HIDDEN MARKOV MODEL; HUMAN; ISRAEL; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW; TAIWAN; UNITED STATES;

CANADA; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DNA; FECES; HUMANS; ISRAEL; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; TAIWAN; UNITED STATES;

EID: 84878766522     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-013-0010-8     Document Type: Review

References (48)

1. Lieberman D. Progress and challenges in colorectal cancer screening and surveillance. Gastroenterology. 2010;138(6):2115-26.
2. Ferlay JP, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. EJC. 2010;46:765-81.
3. Richter S. Fecal DNA screening in colorectal cancer. Can J Gastroenterol. 2008;22(7):631-3.
4. Kanavos P, Schurer W. The dynamics of colorectal cancer management in 17 countries. Eur J Health Econ. 2010;10(Suppl 1):S115-29.
5. Hoff G, Dominitz JA. Contrasting US and European approaches to colorectal cancer screening: which is best? Gut. 2010;59(3):407-14.
6. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58(3):130-60.
7. Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 (corrected). Am J Gastroenterol. 2009;104(3):739-50.
8. Whitlock EP, Lin JS, Liles E, et al. Screening for colorectal cancer: a targeted, updated systematic review for the US Preventive Services Task Force. Ann Intern Med. 2008;149(9):638-58.
9. U.S. Preventive Services Task Force. Screening for colorectal cancer: US preventive services task force recommendation statement. Ann Intern Med. 2008;149(9):627-637.
10. von Karsa L, Julietta P, Segnan N. European guidelines for quality assurance in colorectal screening and diagnosis, 1st edn. (Executive summary): XXXVI-XLVIII.
11. Itzkowitz S, Brand R, Jandorf L, et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol. 2008;103(11):2862-70.
12. Ahlquist DA. Next-generation stool DNA testing: expanding the scope. Gastroenterology. 2009;136(7):2068-73.
13. Loganayagam A. Faecal screening of colorectal cancer. Int J Clin Pract. 2008;62(3):454-9.
14. Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening. Epidemiol Rev. 2011;33(1):88-100.
15. Kisiel JB, Ahlquist DA. Stool DNA screening for colorectal cancer: opportunities to improve value with next generation tests. J Clin Gastroenterol. 2011;45(4):301-8.
16. Pharmacoeconomics. Checklist for authors of modelling studies submitted to Pharmacoeconomics (online). http://adisonline.com/pharmacoeconomics/ documents/PEC-modellingchecklist.pdf. Accessed 12 Dec 2011.
17. Pharmacoeconomics (online). http://adisonline.com/pharmacoeconomics/ Documents/PEC-econ-eval-list.pdf.
18. Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology. 2004;126(5):1270-9.
19. Parekh M, Fendrick AM, Ladabaum U. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia. Aliment Pharmacol Ther. 2008;27(8):697-712.
20. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, et al. Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med. 2010;153(6):368-77.
21. Ahlquist D, Sargent D, Loprinzi C, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008;149(7):441-50.
22. Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology. 2000;119(5):1219-27.
23. Tagore KS, Lawson MJ, Yucaitis JA, et al. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer. 2003;3(1):47-53.
24. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004;351(26):2704-14.
25. Wu GH, Wang YM, Yen AM, et al. Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries. BMC Cancer. 2006;24(6):136.
26. Telford JJ, Levy AR, Sambrook JC, et al. The cost-effectiveness of screening for colorectal cancer. CMAJ. 2010;182(12):1307-13.
27. Ladabaum U, Song K. Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand. Gastroenterology. 2005;129(4):1151-62.
28. Leshno M, Halpern Z, Arber N. Cost-effectiveness of colorectal cancer screening in the average risk population. Health Care Manag Sci. 2003;6(3):165-74.
29. ISPOR-Consolidated Health Economic Evaluation Reporting Standards (still in draft) (online). http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp.
30. Fan JB, Chee MS, Gunderson KL. Highly parallel genomic assays. Nat Rev Genet. 2006;7(8):632-44.
31. Wong CK, Fedorak RN, Prosser CI, et al. The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer. Int J Colorectal Dis. 2012;27(12):1657-64.
32. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007;99(19):1462-70.
33. Osborn NK, Ahlquist DA. Stool screening for colorectal cancer: molecular approaches. Gastroenterology. 2005;128(1):192-206.
34. Exact sciences. Exact sciences 2010 annual report (online). http://investor.exactsciences.com/2010AR/index.html. Accessed 20 Oct 2011.
35. Wilson J, Junger G. Principles and practice of screening for disease (online). http://whqlibdoc.who.int/php/WHO-PHP-34.pdf. Accessed 24 Jan 2012.
36. Weller D, Coleman D, Robertson R, et al. The UK colorectal cancer screening pilot: results of the second round of screening in England. Br J Cancer. 2007;97(12):1601-5.
37. Kewenter J, Brevinge H, Engaras B, et al. Results of screening, rescreening, and follow-up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing. Results for 68,308 subjects. Scand J Gastroenterol. 1994;29(5):468-73.
38. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348(9040):1467-71.
39. Cole SR, Young GP. Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer. Med J Aust. 2001;175(4):195-8.
40. Deutekom M, van Rossum LG, van Rijn AF, et al. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective. Scand J Gastroenterol. 2010;45(11):1345-9.
41. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut. 2010;59(1):62-8.
42. Whitney D, Skoletsky J, Moore K, et al. Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J Mol Diagn. 2004;6(4):386-95.
43. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134(5):1570-95.
44. Schroy PC, 3rd, Lal S, Glick JT, et al. Patient preferences for colorectal cancer screening: how does stool DNA testing fare? Am J Manag Care. 2007;13(7):393-400.
45. Itzkowitz SH, Jandorf L, Brand R, et al. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol. 2007;5(1):111-7.
46. Duffy MJ, van Rossum LG, van Turenhout ST, et al. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J Cancer. 2011;128(1):3-11.
47. Li M, Chen WD, Papadopoulos N, et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol. 2009;27(9):858-63.
48. Zou H, Taylor WR, Harrington JJ, et al. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology. 2009;136(2):459-70.